玻璃体切除术联合视网膜下组织型纤溶酶原激活剂注射治疗黄斑下出血后3个月和1年视力结局的预测因素
这项前瞻性队列研究纳入29例黄斑下出血(SMH)合并新生血管性年龄相关性黄斑变性或视网膜大动脉瘤、接受玻璃体切除术联合视网膜下组织型纤溶酶原激活剂注射并随访至少3个月的眼。结果显示术后3个月最佳矫正视力(BCVA)较基线改善;1年logMAR BCVA与年龄和术后1年内SMH复发相关;2周移位分级与SMH的对比噪声比相关。作者结论认为SMH复发对1年视力结局有负面影响,对比噪声比是早期SMH移位的有用预测因素,但不是1年BCVA的预测因素,需进一步研究确定预防SMH复发的最佳治疗。
要点
- 术后3个月logMAR BCVA从基线0.76(20/115)±0.35改善至0.51(20/65)±0.32(P=0.006)。
- 1年logMAR BCVA与年龄(P=0.007,β=0.39)和术后1年内SMH复发(P<0.001,β=0.65)相关。
- 2周移位分级与SMH的对比噪声比相关(P=0.001,β=-0.54)。
核心结论
- SMH复发对玻璃体切除术联合视网膜下组织型纤溶酶原激活剂注射治疗SMH后的1年视力结局有负面影响。
- 对比噪声比是早期SMH移位的有用预测因素,但不是1年BCVA的预测因素。
- 需进一步研究以确定预防SMH复发的最佳治疗。
研究设计与样本
- 前瞻性队列研究,纳入连续的眼部SMH合并新生血管性年龄相关性黄斑变性或视网膜大动脉瘤、接受玻璃体切除术联合视网膜下组织型纤溶酶原激活剂注射并随访至少3个月的眼。
- 共纳入29例患者的29只眼,年龄73.1±8.4岁;其中新生血管性年龄相关性黄斑变性25只眼。
主要发现
- 术后3个月logMAR BCVA较基线改善:基线0.76(20/115)±0.35 vs 3个月0.51(20/65)±0.32,P=0.006。
- 多变量分析中,1年logMAR BCVA与年龄相关(P=0.007,β=0.39),与术后1年内SMH复发相关(P<0.001,β=0.65)。
- 2周移位分级与SMH的对比噪声比相关(P=0.001,β=-0.54)。
- 黄斑裂孔发生于3只眼(10%),均为小SMH尺寸,均通过额外玻璃体切除术联合内界膜翻转技术闭合。
局限性
- 需进一步研究以确定预防SMH复发的最佳治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate factors associated with 3-month or 1-year best-corrected visual acuity (BCVA) after vitrectomy with subretinal tissue plasminogen activator injection for submacular hemorrhage (SMH) and to identify the predictors of early displacement. METHODS: This prospective cohort study included consecutive eyes with SMH complicating neovascular age-related macular degeneration or retinal macroaneurysm that underwent vitrectomy with subretinal tissue plasminogen activator injection and were followed up for at least 3 months. Parameters that correlated with 3-month BCVA, 1-year BCVA, and 2-week displacement grade (0-3) were identified. RESULTS: Twenty-nine eyes of 29 patients (73.1 ± 8.4 years; neovascular age-related macular degeneration, 25 eyes) were included. Logarithm of the minimum angle of resolution BCVA improved 3 months after the surgery (baseline, 0.76 [20/115] ± 0.35; 3-month, 0.51 [20/65] ± 0.32; P = 0.006). In multivariable analyses, 1-year logarithm of the minimum angle of resolution BCVA correlated with age ( P = 0.007, β = 0.39) and SMH recurrence within 1 year after surgery ( P < 0.001, β = 0.65). Two-week displacement grade correlated with the contrast-to-noise ratio of SMH ( P = 0.001, β = -0.54). Macular hole occurred in three eyes (10%) with small SMH size and was closed in all eyes via additional vitrectomy with an inverted internal limiting membrane flap technique. CONCLUSION: The recurrence of SMH negatively affected the 1-year visual outcome after vitrectomy with subretinal tissue plasminogen activator injection for SMH. The contrast-to-noise ratio was a useful predictor of early SMH displacement, but not of 1-year BCVA. Further research is necessary to determine the optimal treatment to prevent SMH recurrence.
引用
- Miki M, Miyata M, Ooto S, et al. PREDICTORS OF 3-MONTH AND 1-YEAR VISUAL OUTCOMES AFTER VITRECTOMY WITH SUBRETINAL TISSUE PLASMINOGEN ACTIVATOR INJECTION FOR SUBMACULAR HEMORRHAGE. Retina. 2023. PMID: 37490778. doi:10.1097/IAE.0000000000003885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。